European clinical trials of Ziconotide (SNX-111) for severe pain
Source: Neurex announces Third Quarter 1997 Financial Results. Thursday, Nov. 6, 1997
The pivotal studies for SNX-111, which now has been granted the approved generic name Ziconotide, are nearing the completion of patient enrollment. This will allow the assembly of an NDA which the Company hopes to file in mid-1998. Additionally, the Company reported that during the quarter it initiated pivotal European clinical trials of Ziconotide for severe pain.
Neurex Corporation is developing products for acute care,
principally in the area of cardiorenal and neurological disease. Ziconotide
is in the final stages of Phase III human trials for analgesia and Phase III trials
have been initiated for head trauma. Both CORLOPAM and Ziconotide
have potential in multiple indications. The Company's strategy is to discover, develop and
commercialize its products for acute care treatment in hospital settings, such
as emergency rooms, intensive care units and pain clinics.
Do you have any positive comments or/and questions ? Please send to Dr. Bruce Livett
Copyright © 1998 Dynamix@WORK! All rights reserved. Last updated on December 17, 2003.